CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (42,494)	$ (29,799)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	12	21
Amortization of contract asset		101
Change in right-of-use asset	302	217
Stock-based compensation expense	3,723	2,748
Foreign currency loss	1,305	410
Change in fair value of restricted stock liability		(204)
Changes in operating assets and liabilities:
Prepaid expenses and other assets	382	(87)
Research and development incentive receivable	(212)	(1,576)
Deferred offering costs		209
Accounts payable and accrued expenses	2,167	4,873
Deferred revenue		(1,125)
Lease liability	(303)	(229)
Other long term assets and deposits	(912)
Net cash used in operating activities	(36,030)	(24,441)
Cash flows from financing activities:
Proceeds from the issuance of common stock and prefunded warrants, net of offering costs - September 2021 Public Offering		97,222
Proceeds from the exercise of common stock warrants		54
Proceeds from the exercise of stock options		4
Payment of deferred costs	(210)
Net cash provided by (used in) financing activities	(210)	97,280
Effect of exchange rate changes on cash and cash equivalents	(368)	(139)
Net increase (decrease) in cash and cash equivalents	(36,608)	72,700
Cash and cash equivalents at beginning of period	114,916	52,071
Cash and cash equivalents at end of period	78,308	124,771
Supplemental disclosure of non-cash financing activities:
Offering Costs in accounts payable and accrued expense - September 2021 Public Offering		$ 394
Remeasurement of right-of-use asset and lease liability	$ 609